Afuresertib hydrochloride

• CAT Number: I000266
• CAS Number: 1047645-82-8
• Molecular Formula: C₁₈H₁₇Cl₂FN₄OS • HCl
• Molecular Weight: 463.80
• Purity: ≥95%
• Synonyms: GSK2110183B
• Solubility: DMSO: ≥ 52 mg/mL
• Storage: Store at -20°C
• IUPAC Name: N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)thiophene-2-carboxamide;hydrochloride
• InChI: InChI=1S/C18H17Cl2FN4OS.ClH/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10;/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26);1H/t12-;/m0./s1
• InChIKey: YFQJOPFTGMHYNV-YDALLXLXSA-N
• SMILES: CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)N[C@@H](CC3=CC(=CC=C3)F)CN)Cl.Cl

Afuresertib hydrochloride（Cat No.:I000266）is a potent and selective inhibitor of AKT, a key kinase in the PI3K/AKT/mTOR signaling pathway, which regulates cell growth, survival, and metabolism. By inhibiting AKT, Afuresertib disrupts these essential processes, making it valuable for cancer research, particularly in tumors with dysregulated AKT activity. This compound has shown promise in preclinical and clinical studies for treating various cancers, including multiple myeloma and solid tumors. Afuresertib is widely used to explore AKT-targeted therapies and resistance mechanisms in cancer treatment, contributing to the development of precision oncology strategies.

Reference

[1]. Spencer A, et al. Novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma: Phase 1 study results. Blood. 2014 Jul 29. pii: blood-2014-03-559963.